Gene Therapy - Helen Anderson
Gene therapy is not a single technology. It can mean repairing a mutation, adding a functional gene without permanently altering the genome, or editing a long-lived stem cell so that every cell it produces carries a therapeutic change. In this conversation, Bálint of SciAnts_Streams speaks with genetic counselor and science communicator Helen Anderson of Fred Hutch about how these strategies move from molecular biology into medicine.
The discussion examines CRISPR-Cas9, base editing, viral vectors, and the biological problem of delivering an edit to exactly the cells that need it. Helen breaks down a glioblastoma strategy that pairs an engineered cytosine deaminase with the conversion of 5-FC into the chemotherapy drug 5-FU, illustrating both the ingenuity of targeted gene therapy and the reality that promising early clinical results do not always survive larger trials.
The episode then turns to HIV and CCR5: how naturally occurring changes in this receptor helped reveal a potential route to resistance, why the Berlin patient became so important to HIV research, and how researchers are now exploring gene editing as a way to recreate that biology without requiring a high-risk bone marrow transplant. The result is a grounded look at what gene therapy can actually do—and why delivery, safety, durability, and access matter as much as the edit itself.
Fred Hutchinson Cancer Center Socials
Homepage: https://www.fredhutch.org/
Facebook: https://www.facebook.com/HutchinsonCenter
X: https://x.com/fredhutch
LinkedIn: https://www.linkedin.com/company/fredhutch/
TikTok: tiktok.com/@fredhutch
YouTube: https://www.youtube.com/fredhutch
Instagram: https://instagram.com/fredhutch